BTOG 2019 | MARS2 trial: radical surgery for mesothelioma

Eric Lim

Eric Lim, MD, of the Royal Brompton & Harefield NHS Foundation Trust, London, UK, discusses the Mesothelioma and Radical Surgery 2 (MARS2; NCT02040272) trial, which is investigating whether pleurectomy/decortication confers a survival advantage. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland.

Share this video